Nplate (romiplostim)

P=N/A, N=45, The First Affiliated Hospital of Xiamen University; The First Affiliated Hospital of Xiamen University

We diagnosed the patient with moderately severe AA and observed hematopoietic recovery following treatment with anabolic steroids and eltrombopag...Cyclosporine and romiplostim treatment were effective, allowing for outpatient management. In the two cases described herein, a small number of PNH-phenotype cells were confirmed. The clinical importance of the small PNH-phenotype populations and the mechanism underlying AA during OSIM therapy remain unclear and warrant further investigation.

P2, N=66, Recruiting, The First Affiliated Hospital of Soochow University | Not yet recruiting --> Recruiting

P3, N=88, Recruiting, The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting --> Recruiting

P2, N=11, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Apr 2026 | Trial primary completion date: Dec 2026 --> Apr 2026

P2, N=136, Recruiting, Nantes University Hospital | Not yet recruiting --> Recruiting | Trial completion date: Apr 2028 --> Dec 2028 | Initiation date: Jan 2026 --> Sep 2026 | Trial primary completion date: Apr 2028 --> Dec 2028

Romiplostim-induced MF in a mouse model demonstrated extensive bone marrow (BM) CHI3L1 mRNA expression, which was reversed by clodronate treatment. A culture assay revealed that high CHI3L1 concentrations promoted extracellular matrix production by fibroblast cell lines, and that a CHI3L1-neutralizing antibody abrogated this effect. These results indicate the importance of CHI3L1 in the association between fibrocytes and fibroblasts in MF and could be a focus for future treatment.

P2, N=164, Not yet recruiting, Novartis Pharmaceuticals | Trial completion date: Aug 2030 --> Mar 2030 | Trial primary completion date: Dec 2028 --> Jun 2028

P2, N=164, Not yet recruiting, Novartis Pharmaceuticals

P1/2, N=136, Not yet recruiting, Centre Hospitalier Universitaire De Nantes

P2, N=66, Not yet recruiting, The First Affiliated Hospital of Soochow University

Supportive care included epoetin alfa, romiplostim, iron, and vitamin supplementation. CONCLUSIONS This is the first known reported case that demonstrates the feasibility and effectiveness of a chemotherapy-free induction strategy using inotuzumab and blinatumomab for frontline treatment of Ph-negative B-ALL in Jehovah's Witness patients. It shows that MRD negativity can be safely achieved without cytotoxic chemotherapy or transfusion support and supports the use of the ALLIANCE A041703 trial regimen as a treatment model for this unique and underserved patient group.